ReviewFrontiers in microbiology2020
Review in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- The Role of Probiotics in the Treatment of Vulvovaginal Candidiasis: A Systematic Review and Meta-Analysis.Ethiopian journal of health sciences · 2023Pooled it
- The role of probiotics in restoring and maintaining vaginal microbiome health: a review.Infection and immunity · 2026Review
- Intravaginal Formulation Strategies for Vaginal Disorders: Optimizing Phytochemical and Biological Preparations-A Review.Molecules (Basel, Switzerland) · 2026Review
- Untargeted Metabolomic Analysis of Cell-Free Supernatants (CFSs) from Different Clinical Isolates ofJournal of fungi (Basel, Switzerland) · 2026Article
- Multi-kingdom cervical microbiome structure in health and dysbiosis: a cross-sectional study from Kazakhstan.Frontiers in microbiology · 2026Article
- Probiotic-Based Materials as Living Therapeutics.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- The vital role of Lactobacillus sp. in vaginal health: Implications for enhanced prophylactic research.Probiotics and antimicrobial proteins · 2026Review
- Characteristics of Two Saccharomyces cerevisiae Strains and Their Extracellular Vesicles as New Candidates for Probiotics.Probiotics and antimicrobial proteins · 2026Article
- Non-albicans Candida in Vulvovaginal Candidiasis: Antifungal Resistance and Expression of ERG11, CDR1, CDR2, and MDR1 Genes.MicrobiologyOpen · 2025Article
- Enabling technologies for in situ biomanufacturing using probiotic yeast.Advanced drug delivery reviews · 2025Review
- New insights toward personalized therapies for vulvovaginal candidiasis and vaginal co-infections.Frontiers in microbiology · 2025Review
- Article
- Review
- Licochalcone A Protects Vaginal Epithelial Cells Against Candida albicans Infection Via the TLR4/NF-κB Signaling Pathway.Journal of microbiology (Seoul, Korea) · 2024Article
- Multifactorial inhibition of Candida albicans by combinations of lactobacilli and probiotic Saccharomyces cerevisiae CNCM I-3856.Scientific reports · 2024Article
- Review
- Article
- Evaluation of the activity of antimicrobial peptides against bacterial vaginosis.Open life sciences · 2024Article
- Microbiota Transplant and Gynecological Disorders: The Bridge between Present and Future Treatments.Microorganisms · 2023Review
- An Inter-Cooperative Biohybrid Platform to Enable Tumor Ablation and Immune Activation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaginal infections affect 70% of women during their lifetimes and account for millions of annual doctors' visits. These infections are predominantly represented by vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV). Although standard antimicrobial agents remain the major strategy for the prevention and treatment of vaginal infections, both VVC and BV are difficult to treat due to high rates of resistance and recurrence, high probability of complications, and negative effects on the vaginal microbiota. This review focuses on a new approach of yeast-based probiotics for the prevention and/or treatment of these common vaginal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.